Press Releases May 1, 2026 08:00 AM

Aemetis to Review First Quarter 2026 Financial Results on May 7, 2026

Aemetis schedules Q1 2026 earnings review conference call for May 7, 2026

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
AMTX

Aemetis, Inc., a US-based renewable natural gas and biofuels company, announced a conference call to review its Q1 2026 financial results on May 7, 2026. The call will provide investors with updates on company operations including its biogas and biofuel production facilities and ongoing projects in sustainable aviation fuel and CO2 sequestration.

Aemetis to Review First Quarter 2026 Financial Results on May 7, 2026
AMTX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Aemetis focuses on renewable natural gas and biofuels across multiple facilities in California and India.
  • The company is expanding its biogas digester network and operates ethanol and biodiesel production plants.
  • Upcoming sustainable aviation fuel and CO2 sequestration projects show the company’s commitment to emission reductions and innovation.

CUPERTINO, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Aemetis, Inc. (NASDAQ: AMTX) announced that the company will host a conference call to review the release of its first quarter 2026 earnings report:

Date: Thursday, May 7, 2026

Time: 11 am Pacific Time (PT)

Live Participant Dial In (Toll Free): +1-888-506-0062 entry code 943189 

Live Participant Dial In (International): +1-973-528-0011 entry code 943189

Webcast URL: https://www.webcaster5.com/Webcast/Page/2211/53904

Attendees may submit questions during the Q&A (Questions & Answers) portion of the conference call.

The webcast will be available on the Company’s website (www.aemetis.com) under Investors/Conference Calls, along with the company presentation, recent announcements, and video recordings.

The voice recording will be available through May 21, 2026 by dialing (Toll Free) 877-481-4010 or (International) 919-882-2331 and entering conference ID number 53904. After May 21st, the webcast will be available on the Company’s website (www.aemetis.com) under Investors/Conference Calls.

About Aemetis

Headquartered in Cupertino, California, Aemetis is a diversified renewable natural gas and biofuels company focused on the development and operation of innovative technologies that lower energy costs and reduce emissions. Founded in 2006, Aemetis is operating and expanding a California biogas digester network and pipeline system to convert dairy waste gas into Renewable Natural Gas. Aemetis owns and operates a 65 million gallon per year ethanol production facility in California’s Central Valley near Modesto that supplies about 80 dairies with animal feed. Aemetis owns and operates an 80 million gallon per year production facility on the East Coast of India producing high quality biodiesel and refined glycerin. To utilize the byproducts from ethanol production, Aemetis is developing a sustainable aviation fuel plant and a CO2 sequestration project in California. For additional information about Aemetis, please visit www.aemetis.com. 

Investor Relations/Media Contact:
Todd Waltz
(408) 213-0940
[email protected]

External Investor Relations Contact:
Kirin Smith
PCG Advisory Group
(646) 863-6519
[email protected]


Risks

  • The company’s financial performance and outlook unknown until earnings release, leading to uncertainty among investors.
  • Execution risks related to new projects, including sustainable aviation fuel and CO2 sequestration initiatives.
  • Market and regulatory conditions in renewable energy and biofuels sectors can impact operational performance and expansion prospects.

More from Press Releases

Texxon Holding Limited Announces Commencement of Operations at Henan Polystyrene Production Facility, A Milestone in Manufacturing Expansion Strategy Jul 7, 2026 Columbia Financial, Inc. Commences Firm Commitment Underwritten Offering Jul 7, 2026 Diana Shipping Inc. Announces Time Charter Contract for m/v Medusa with Aquavita Jul 7, 2026 Virtuix Signs Strategic Partnership with Sirica Therapeutics to Advance AI-Driven Autism Therapy Jul 7, 2026 XWELL Announces Definitive Agreement to Divest XpresSpa and XpresTest Businesses Jul 7, 2026